Next 10 |
2024-03-24 07:39:48 ET Summary Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. ...
2024-03-23 08:20:06 ET Summary Pandemic era CpG 1018 revenues are gone and unlikely to rekindle. HEPLISAV-B revenues create a reliable growing stream of income. Dynavax is fairly valued. I have followed the changing fortunes of Dynavax ( DVAX) since 01/2017...
2024-03-22 01:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-11 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference PR Newswire EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializin...
2024-02-22 20:00:16 ET Image source: The Motley Fool. Dynavax Technologies (NASDAQ: DVAX) Q4 2023 Earnings Call Feb 22, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Dynavax Technologies (DVAX) Q4 2023 Earnings Call Tr...
2024-02-22 19:34:06 ET Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Conference Call February 22, 2024 04:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer ...
2024-02-22 16:02:21 ET More on Dynavax Dynavax Technologies: Still A Solid Pick For 2024 Dynavax reports 46% Y/Y increase in HEPLISAV-B vaccine net product revenue Seeking Alpha’s Quant Rating on Dynavax Historical earnings data for Dynavax Fin...
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance PR Newswire HEPLISAV-B ® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key seg...
2024-02-21 17:20:36 ET More on Dynavax Dynavax Technologies: Still A Solid Pick For 2024 Dynavax reports 46% Y/Y increase in HEPLISAV-B vaccine net product revenue Seeking Alpha’s Quant Rating on Dynavax Historical earnings data for Dynavax Fin...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
2024-03-22 01:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-11 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference PR Newswire EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializin...